- A systematic review and meta-analysis suggest that adalimumab (Humira) is associated with a higher incidence of adverse events (AEs), but not serious AEs or discontinuation in patients with psoriasis.
Why this matters
- Robust safety information can help guide treatment decisions.
- Adalimumab was associated with higher incidence of AEs (15 trials; relative risk [RR], 1.05; 95% CI, 1.00-.109), infection (14 trials; RR, 1.10; 95% CI, 1.02-1.20), and injection site reaction (6 trials; RR, 1.80; 95% CI, 1.18-2.74) compared with control treatment.
- Adalimumab and control treatment were associated with similar incidence of serious AEs (16 trials; RR, 1.06; 95% CI, 0.70-1.48), serious infection (9 trials; RR, 1.22; 95% CI, 0.61-2.44), and discontinuation caused by AE (13 trials; RR, 1.12; 95% CI, 0.80-1.57).
- No significant publication bias was observed by Egger’s test (P=.299).
- Patients with psoriasis, 3917 treated with adalimumab and 2583 control patients, from 20 RCTs were included in this meta-analysis of clinical safety.
- Funding: None disclosed.
- Heterogeneity between included studies.